Get access to more insightful information

By signing up to Upstox today
Shareholding Info
  • Promoters
    60.64 %
  • Foreign institutions-FII
    6.55 %
  • Other domestic institutions
    5.2 %
  • Retail and other
    18.3 %
  • Mutual Funds
    9.31 %

Biocon India Pvt. Ltd

Biocon India Pvt Ltd is a biotechnology company engaged in all phases of the product cycle from the discovery to the development and commercialisation of the drug.

The company was incorporated as a joint venture between Kiran Mazumdar-Shaw and Biocon Biochemicals Ltd Ireland in 1978. The company started in Bengaluru with just three employees. It began manufacturing and exporting papain, a plant enzyme, and isinglass, a marine hydrocolloid – both key products for the brewing industry.

Two years later, Biocon laid the foundation of its campus in Bengaluru to expand its operation. The building to date is home to the company's corporate office. In 1984, a year after the construction of the company's head office, Biocon established its R&D division, which initially focused on the development of solid-state fermentation technology to develop novel enzymes.

In 1989, Biocon Biochemicals Ltd, Ireland, along with its subsidiaries was acquired by Unilever plc and merged with its wholly-owned subsidiary Quest International. This paved the way for Biocon India to produce enzymes for Unilever’s food businesses.

Business operations

Biocon India became the first life science company in the country to get ISO 9001 Certification. The company incorporated Syngene as a custom research organisation (CRO) in 1994 to provide efficient, high-quality, cost-effective research and development services in chemistry and biology.

In 1998, Biocon became an independent company after Kiran Mazumdar-Shaw and John Shaw bought Unilever’s share in the company.

At the turn of the century, Biocon established Clinigene as India's first clinical research organisation.

In 2002, Biocon established a joint venture company, Biocon Biopharmaceuticals Pvt Ltd, with CIMAB S.A., a Cuban biotechnology company.

Biocon went public with a successful IPO in 2004. On the day of the listing, the company crossed a market value of $1.1 billion, making Biocon only the second Indian company to do so.

In 2006, the company inaugurated Biocon Park, India's first biotechnology special economic zone (SEZ).

Biocon divested its legacy enzymes business to Novozymes for $115 million in 2007 to increase focus on developing, and manufacturing biopharmaceuticals.

Biocon launched Insulin Glargine under the brand name Basalog in India in 2009, offering diabetes patients an advanced, affordable insulin therapy.

The company’s research organisation, Syngene made a debut on the Indian stock market in 2015.

Biocon Biologics approved a primary equity investment by True North in 2020. The same year, Tata Capital picked up a minority stock in Biocon Biologics. Biocon Biologics also received a $150 million capital injection from Goldman Sachs.

Biocon's market capitalisation stands at over ₹30,399 crore as of December 20, 2023. Biocon Ltd's share price has plunged over 47% in the last three years.

Financial Highlights

  • The total income of the company for FY23 stood at ₹11,550 crore, up by 38% year-on-year.
  • The firm reported a profit of ₹462.7 crore in FY23.
  • The EBITDA (earnings before interest, taxes, depreciation and amortisation) stood at ₹2,887.6 crore in FY23.
  • The EBITDA margin stood at 25% in FY23.
  • The company made a total capital expenditure of ₹530 crore in FY23.
  • Its earnings per share (EPS) increased to ₹3.9 in FY23.
Download Icon Download the Upstox App Today

Download Upstox Mobile App